FDA Grants Orphan Drug Designation For 3,4-DAP
BioMarin has announced that the FDA has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.